Solara Active Pharma shares surge 2% on USFDA inspection clearance

Solara Active Pharma Sciences Ltd shares surged around 2% after the company announced that the United States Food and Drug Administration (USFDA) has completed the inspection at its multipurpose API manufacturing facility in Visakhapatnam, Andhra Pradesh.

The inspection established that the site is in an “acceptable state of compliance,” with zero Form 483 inspectional observations issued.


The Visakhapatnam facility, a greenfield project spread over 40 acres, houses facilities for the manufacture of Ibuprofen API.

Poorvank Purohit, the Managing Director and CEO of Solara Active Pharma Sciences, expressed his satisfaction, stating, “This is the second US FDA inspection we have undergone at this site. We remain agile to the increasing requirements on quality and compliance, and I am confident that we will sustain our quality culture and anchor it further.”

The successful USFDA inspection clearance without any observations highlights Solara Active Pharma’s commitment to maintaining high quality standards and adhering to regulatory compliance.

As of 11:30 AM, the company’s shares were trading 2.17% higher at ₹494.60 on the National Stock Exchange (NSE).